PATIENTS: A PROSPECTIVE RANDOMIZED PHASE III STUDY CHEMOTHERAPY IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA USE OF MYELO-ABLATIVE THERAPY FOLLOWING INTENSIFIED OVERALL AND EVENT-FREE SURVIVAL ARE NOT IMPROVED BY THE